Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Covidien reports positive study results for embolization device

Covidien Pipeline Embolization device has showed positive results both in terms of safety and effectiveness from its PUFS (Pipeline for Uncoilable or Failed AneurysmS) study in the treatment of uncoiled or failed aneurysms.

The device met the end points in the six-month, single-arm, 108-patient study.

The device features flow diversion in which the pipeline device disrupts the flow of blood from the parent artery into the aneurysm, and re-endothelialization where the device forms a scaffold upon which endothelial cells can grow.

The Pipeline Embolization device has obtained premarket approval in April 2011 and is indicated for the endovascular treatment of adults who are aged 22 years or older.